The Animal Model Market

Animals are used as “models” for studying human biology and diseases, to test drugs and vaccines. Most of these animals are specifically bred for research purposes, although they are also obtained from other sources. For example, in Australia “surplus” dogs from the greyhound racing industry have ended up in research labs.

Although animals have proven poor models for human disease research, and only around 5% of drugs that are safe and effective in animals are suitable for humans, the animal model market is a big industry. Mice and rats (murine models) are the most commonly used animals in research labs. Other animals bred for research purposes include, for example, monkeys, pigs, dogs, cats, and rabbits. The main applications include physiology, toxicology, cancer research, neurological research, biomedical research, genetic research, and xenotransplantation.

The Animal Model Market does not only include the breeding and sale of animals; the animals also need cages, feed, bedding, and other care products.

The end users in this market are pharmaceutical companies, research institutes, contract research organisations, and educational institutes.

Different types of mice and rats are for sale. For example:

  • inbred mice, genetically engineered mice, conditioned/surgically modified mice, hybrid/congenic mice, outbred mice, spontaneous mutant mice
  • knockout, outbred, inbred, hybrid, immunodeficient, conditioned rats.

Adelaide University’s Laboratory Animal Services provide a price list “for inbred, outbred and hybrid rodents for internal clients and external clients”. Prices range from $3.24 for outbred new born mice under 6 days to $80.80 for a time mated Hybrid F1 mouse.

The following is a collection of quotes (grammatical errors included) from websites that provide/sell information about the Animal Model Market.

Animal model market: Market wise overview

Animal models are emerging globally and there is a growing trend in the usage of animal models in drug discovery. Rapid advancement in the novel technology made the animal models constructive and easy. The market witness high competitiveness and high capital investment with animal models. Even though high cost of animal model research it never hampers the growth. The high incidence rate of diseases and adverse effects of the drugs drives the market towards animal models to ensure the safety of the humans. Other factors the contributing the growth of the animal model includes government involvement in research and research institutes for development of standard protocols for animal models.


Obese diabetic mouse. Source: Flickr/Mycroyance


Mice Model Market is poised to reach USD 1.59 Billion by 2021 with 7.5% CAGR during the forecast period of 2016-2021.

In 2016, North America is expected to account for the largest share of the market, followed by Europe, Asia-Pacific, and the Rest of the World (RoW). North America’s large share is attributed to the rising demands for monoclonal antibody production, continued and responsible use of animals ensured by animal care organizations, rising preclinical activities by CROs and pharmaceutical companies, growing stem cell research in Canada, and government support for the development of protein drugs in Canada.

CAGR = compound annual growth rate

The mice model market is projected to reach USD 1.59 Billion by 2021 from USD 1.11 Billion in 2016, at a CAGR of 7.5% in the next five years (2016 to 2021). The growth of the market can be attributed to ongoing innovations in mice models, continuous support in the form of investments and grants, and growing demand for humanized mice models. In the coming years, the mice models market is expected to witness the highest growth rate in the Asia-Pacific region. The high growth in the region can be attributed to less stringent regulations on the use of animal models for research in the region, international alliances for R&D activities in China, growth in regenerative medicine, biomedical, and medical research in Japan, growing presence of global players, development of bioclusters to boost the biotechnology industry in India, ongoing biomedical research activities in Australia, and rising pharmaceutical & biotechnology R&D activities.

Mice Model Market Drivers:

  • Ongoing innovations in mice models
  • Mice models for immune diseases
  • Mice models for cancer
  • Mice models for rare diseases
  • Growing consumption of personalized medicine driving the demand for humanized mice models
  • Continuous support in the form of grants and investments
  • Growing number of pharmaceutical R&D activities
  • Increasing focus of associations on the development of embryonic stem cells as well as knockout and mutant mice
  • International Mouse Phenotyping Consortium (IMPC)
  • International Knockout Mouse Consortium (IKMC)

Mice Model Market Restraints:

  • Growing use of rat models
  • Increased benefits from cryopreservation
  • Regulations and laws for ethical use of animals in research
  • The Animal Welfare Act
  • Public Health Service Policy on Humane Care and Use of Laboratory Animals

Mice Model Market Challenge:

  • Development of alternative methods to animal testing
  • Advancements in zebrafish model development
  • Growing need for improved mice models

Stakeholders of the Mice Model Market 

  • Mice models and services companies
  • Mice model and services distributors
  • Animal care products manufacturers and suppliers
  • Out–licensing life sciences companies (Pharmaceutical/Biopharmaceutical/Biotechnology)
  • In–licensing life sciences companies (Pharmaceutical/Biopharmaceutical/Biotechnology)
  • Clinical research organizations (CROs)
  • Academic institutes
  • Government and private research institutes
  • Medical research centers
  • Public and private animal health agencies
  • Animal care associations
  • Business consultancies
  • Venture capitalists



The global rat model market size was valued at USD 412.3 million in 2016 and is expected to grow at a CAGR of 8.3% over the forecast period. Growing development of new medical devices and biotechnological products is anticipated to support growth of the market.

The rising incidence of chronic conditions, introduction of new infectious strains, and growing healthcare economic burden over matured regions such as North America are expected to boost the research activities within the area.

On the contrary, possibility of research at reduced cost in countries such as Japan, India, Thailand, and Singapore is anticipated to promote growth of the rat model industry within the Asia Pacific region. The region is expected to hold over 10.0% of the share by 2025.


The Animal Model Market is an industry of substantial size with many stakeholders. Continuation and market expansion is in their interest. Can we expect stakeholders in this market to acknowledge the limitations of animal research, phase out animal experiments and use more human-relevant models?

It is difficult to get a man to understand something, when his salary depends upon his not understanding it!



3 thoughts on “The Animal Model Market

  1. Pingback: Animal-based research and a plant-based diet – the links. – SAFE Talk Blog

  2. No

    Sorry, but I stopped reading after your claim that only 5% of drugs that are safe in animals are also safe in humans. I would like to see your source. Every single FDA approved drug on the market HAS to be animal tested or it does not go to clinical trials. Which means that every single FDA approved drug on the market, was tested in animals.

    1. ozsheba Post author

      Hi there, one source supporting the claim that only 5% of new drugs that have been tested in animals and were found to be safe are also safe in humans: US Dept of Health & Human Services, National Center for Advancing Translational Sciences: “Therapeutic development is a costly, complex and time-consuming process. The average length of time from target discovery to approval of a new drug is about 14 years. The failure rate during this process exceeds 95 percent, and the cost per successful drug can be $1 billion or more.”

      This review found that “the average rate of successful translation from animal models to clinical cancer trials is less than 8%”. Mak, I W; N Evaniew, and M Ghert (2014). Lost in translation: animal models and clinical trials in cancer treatment. American Journal of Translational Research 6 (2):114-118.

      “In 2004, the FDA estimated that 92 percent of drugs that pass preclinical tests, including “pivotal” animal tests, fail to proceed to the market. More recent analysis suggests that, despite efforts to improve the predictability of animal testing, the failure rate has actually increased and is now closer to 96 percent. The main causes of failure are lack of effectiveness and safety problems that were not predicted
      by animal tests.” Akhtar, A (2015). The flaws and human harms of animal experimentation. Cambridge Quarterly of Healthcare Ethics 24 (04):407-419. doi: 10.1017/S0963180115000079.

      For more research articles and/or government reports supporting the claim that animal experiments do not translate well to humans go to this website and search for ‘bias’ :


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s